
Amphista Therapeutics have appointed Beverley Carr Chief Business Officer. Amphista is a leader in next generation targeted protein degradation (TPD) …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

